Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial - Camidge, DR; Kim, HR; Ahn, M-J (J Thorac Oncol, 2021)
et al.